Integrated and continuous manufacturing technologies have shown critical advantages, including enhanced speed to market, assurance of quality through automation, security and flexibility of supply through scaling and decentralization of manufacturing, and reduced cost of goods. Over the past 15 years, the Myerson group contributed to several efforts in integrated continuous manufacturing, including the first end-to-end continuous pharmaceutical process in 2011 and the Pharmacy on Demand project in 2016. Current collaborative activities are focused on process intensification and of unit operations, including crystallization, filtration, drying, membrane separation.
